HAE
HAEMONETICS CORPPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 22 ▲ B of A Securities upgrades
- Sep 17 ▲ Citigroup upgrades
- Sep 30 ▲ 3 funds open new positions (13F)
- Sep 30 Haemonetics Corporation v. Terumo BCT, Inc.
- Oct 19 FDA: Haemonetics Announces FDA Approval of PerQseal® Elite Vasc…
- Oct 19 ▲ Haemonetics received FDA approval for its PerQseal Elite vascular cl…
- Nov 5 ▲ Haemonetics reported Q2 fiscal 2027 revenue of $357.8M, up 9.3% YoY,…
- Nov 11 ▼ 1 insider sell $101.1K at $120.99
- Nov 13 Jefferies initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $101.1K.
- InstitutionsBULLISH
Q3 2026: 31 added (3 new), 17 trimmed or exited. Largest new: Jane Street Group $34.2M.
- AnalystsBULLISH
12 of 15 rate it Buy or better.
- Short sellersSTEADY
Short interest +5.0% to 3.60M shares. 6.3 days to cover, ≈7.9% of shares.
- TrendUPTREND
7% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | $89.9M |
| FMR LLC | ADD | $53.2M |
| Assenagon Asset Management S.A. | DOUBLED | $47.8M |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | TRIM | $47.5M |
| Boston Trust Walden Corp | TRIM | $40.6M |
| Allspring Global Investments Holdings, LLC | TRIM | $37.9M |
| JANE STREET GROUP, LLC | NEW | $34.2M |
| Boston Partners | TRIM | $27.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 13, 2026 | Jefferies INITIATE | Buy |
| Nov 6, 2026 | Citigroup MAINTAIN | Buy |
| Nov 6, 2026 | Barrington Research MAINTAIN | Outperform |
| Nov 5, 2026 | BTIG MAINTAIN | Buy |
| Oct 9, 2026 | Barrington Research MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Maunsell Farris Maryanne VP, Chief Accounting Officer Nov 11, 2026 | EXERCISE | $95.2K |
Maunsell Farris Maryanne VP, Chief Accounting Officer Nov 11, 2026 | TAX W/H | $208.8K |
Maunsell Farris Maryanne VP, Chief Accounting Officer Nov 11, 2026 | EXERCISE | $61.7K |
Maunsell Farris Maryanne VP, Chief Accounting Officer Nov 11, 2026 | EXERCISE | $30.4K |
Maunsell Farris Maryanne VP, Chief Accounting Officer Nov 11, 2026 | SELL | $101.1K |
Galvin Roy EVP, Chief Commercial Officer Oct 30, 2026 | TAX W/H | $17.5K |
Pomeroy Claire Director Jul 24, 2026 | AWARD | 2,538 sh |
KROLL MARK W Director Jul 24, 2026 | AWARD | 2,538 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 1 press release · 4 bullish · 0 bearish · 9 neutral- NEUTRAL 144Nov 12, 2026
Maryanne Maunsell Farris, an officer of Haemonetics, filed a Form 144 notice of intent to sell 836…
The filing is a routine Form 144 notice for a small share sale by an officer. No material impact on the stock is expected. Monitor for any subsequent Form 4 filings to confirm the sale was executed.
- BULLISH 8-KNov 5, 2026
Haemonetics reported Q2 fiscal 2027 revenue of $357.8M, up 9.3% YoY, and adjusted EPS of $1.35…
The raised guidance reflects accelerating momentum in the Plasma/Apheresis segment, which posted 17.7% organic growth. Watch for continued execution on the CSL relationship and margin trajectory, as…
- BULLISH PRESS-RELEASENov 5, 2026
The company raised its full-year revenue guidance to $1.415B-$1.435B from $1.395B-$1.425B…
The raised guidance and solid beat across both top and bottom lines suggest momentum in plasma and MedSurg segments. Watch for continued execution on NexSys adoption and any commentary on hospital…
- BULLISH INST-CLUSTEROct 20, 2026
A bullish institutional cluster formed in HAE during Q3 2026, with three asset managers adding…
The cluster is 75% buyer-driven by dollar count but dominated by a single fund (Assenagon) whose 1,192% position increase is unusually large. Monitor upcoming 13F filings to see if this conviction…
All HAE filing & press-release reports (14)
- 144 reportNov 12, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportOct 20, 2026
- PRESS-RELEASE reportOct 19, 2026
- INST-CLUSTER reportOct 12, 2026
- 8-K reportOct 8, 2026
- PRESS-RELEASE reportSep 30, 2026
- COURT-RULING reportSep 30, 2026
- 8-K reportAug 18, 2026
- DEFA14A reportJun 9, 2026
- 8-K reportJun 5, 2026
- 8-K reportMay 7, 2026
- 8-K reportMay 1, 2026